Compare IMNM & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | BCRX |
|---|---|---|
| Founded | 2006 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2020 | 1995 |
| Metric | IMNM | BCRX |
|---|---|---|
| Price | $22.03 | $8.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $32.80 | $20.82 |
| AVG Volume (30 Days) | 915.1K | ★ 4.5M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.40 | ★ 381.40 |
| EPS | ★ N/A | N/A |
| Revenue | $6,941,000.00 | ★ $25,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,127.34 | $12.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.96 | $6.00 |
| 52 Week High | $27.65 | $11.31 |
| Indicator | IMNM | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 42.58 |
| Support Level | $19.23 | $7.94 |
| Resistance Level | $23.24 | $8.68 |
| Average True Range (ATR) | 1.27 | 0.46 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 55.07 | 34.89 |
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.